interim data from can-003 clinical trial, page-4

Hi Grenfire,

I missed your earlier post. No, I don't hold zero optimism.

It's really a balancing of the risk. There is a chance that there will be a significantly good result, it's just my analysis indicates that the balance of probability is that the result may be non significant with a trend which will be clinically insignificant. eg something like a benefit of 30 days which is not statistically insignificant. These comments relate to the can-003 study. That sort of result increases the risk on other clinical trials and the regulatory and partnering risk.

There may be other clinical trials which have hope, but it was this study which was providing near-term hope of a good result and increase in SP. A lot of investors bought in that hope. My view is that if there is good data to come, it is now further off than I previously thought with a higher risk factor.It may become a buy at some stage, but in my opinion. not yet.